{"disease":{"id":"attr-cm-transthyretin-amyloid-cardiomyopathy","name":"attr cm transthyretin amyloid cardiomyopathy"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"vyndamax-tafamidis-61mg","indication_name":"ATTR-CM (Transthyretin Amyloid Cardiomyopathy)","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyndamax (tafamidis 61mg)","generic_name":"vyndamax-tafamidis-61mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"As prescribed in real world practice","quality_score":0,"revenue":null,"mechanism":"As prescribed in real world practice"}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT04801329","title":"Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT07494656","title":"A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in Germany","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1,"lead_sponsor_name":"Pfizer","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}